Eli Lilly (LLY) has surged to dominate the U.S. GLP-1 weight loss drug market, capturing 60% share, largely due to its successful tirzepatide products, which generated over $12 billion in revenue last quarter. The competitive landscape, however, is heating up as companies like Viking Therapeutics (VKTX) aim to carve out their own niches. Viking is advancing its dual GLP-1/GIP receptor agonist, VK2735, through phase 3 trials, with promising results that could position it as a formidable contender against Lilly and Novo Nordisk.

The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, creating ample opportunity for new entrants. Viking’s unique offering of both injectable and oral formulations sets it apart, but it will need to navigate the challenges of gaining market trust and competing against established players with robust manufacturing capabilities.

For market professionals, the key takeaway is that while Lilly currently leads, Viking’s progress through clinical trials could signal a shift in market dynamics. Should VK2735 receive approval, it could significantly impact Viking’s stock performance, making it a company to watch closely in the evolving weight loss drug sector.

Source: fool.com